Genus PLC
14 July 2026
14 July 2026
Genus plc ("Genus" or the "Group")
FY26 Trading Update - Ahead of expectations
Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the year ended 30 June 2026 ("FY26").
Trading in the second half was better than anticipated, with PIC delivering a strong performance as growth in Asia (including China) and Latin America more than offset weaker performance in North America due to customer disease challenges. ABS also achieved double-digit profit growth with continued benefits from the Value Acceleration Programme offsetting softer customer demand and adverse product mix driven by lower global dairy prices.
As a result, the Group now anticipates FY26 results to be moderately ahead of market consensus1 with adjusted profit before tax of approximately £98m in actual currency, including the final £5.6m milestone payment received earlier in the year from the Group's Chinese partner, Beijing Capital Agribusiness ("BCA").
Cash conversion in the second half was very strong, resulting in significant growth in FY26 free cash flow generation. In fiscal Q4, the Group also received approximately £111m of net cash consideration from BCA following successful formation of the Chinese porcine joint venture earlier in the year. As a result, year-end net leverage will be significantly reduced to approximately 0.4x.
Genus is well placed as it enters FY27 with a substantially strengthened balance sheet and continued focus on delivering its strategic priorities. The Group will announce its FY26 preliminary results on 10 September 2026.
For further information please contact:
Genus plc Tel: +44 (0)125 634 5970
Jorgen Kokke, Chief Executive Officer
Andy Russell, Chief Financial Officer
Anand Date, Investor Relations & Sustainability Director
Tavistock Tel: +44 (0)207 920 3150
Nick Dibden; Katie Hopkins; Saskia Zilkha
About Genus
Genus is a world-leading animal genetics company. Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS2 Resistant Pig is a market leading innovation in gene editing which Genus is looking to commercialise in the porcine industry once further regulatory approvals are obtained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Footnotes
1 The company compiled consensus range for Group FY26 adjusted profit before tax, inclusive of the BCA milestone, is £94.3m to £96.9m with an average midpoint of £95.5m. This is based on analysis of 10 analyst estimates
2 PRRS (Porcine Reproductive and Respiratory Syndrome) Resistant Pig ("PRP")
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.